TOI PRESS-RELEASE SEC Filing Analysis

Final — all horizons settled through T+60d

TOI ▲ +78.52% at T+60d

LONG call ✓ call won +78.52% · α vs SPY +66.91% · entry $2.84 → $5.07

Currently $4.96 · +74.65% from $2.84 entry

Entry anchored
Mar 12, 03:59 PM ET
via Databento tick

T+1d

+20.07%

call +20.07% · α +19.05%

$3.41

settled 3mo ago

T+5d

+16.90%

call +16.90% · α +19.02%

$3.32

settled 3mo ago

T+20d

+16.20%

call +16.20% · α +12.61%

$3.30

settled 2mo ago

T+60d

+78.52%

call +78.52% · α +66.91%

$5.07

settled yesterday

Price Chart

Loading chart...

Executive Summary

The Oncology Institute (TOI) reported strong fourth-quarter and full-year 2025 financial results, with Q4 revenue up 41.6% YoY to $142.0 million and full-year revenue up 27.8% to $502.7 million. Net loss narrowed significantly in Q4 to $7.5M from $13.2M, and Adjusted EBITDA turned positive at $147K. The company reaffirmed 2026 guidance with revenue expected between $630M–$650M and a target for full-year positive Adjusted EBITDA, driven by expansion in capitated care contracts.

Key Financial Metrics

Revenue

$142.0M

+41.6% YoY

EPS

$-0.06

Guidance

$630M-$650M

maintained

Actionable Insight

TOI is showing accelerating revenue growth and meaningful progress toward profitability. Traders should monitor Q1 2026 Adjusted EBITDA (guided to be negative due to seasonality) but expect improvement through the year. The capitated model expansion and strong specialty pharmacy run-rate support the bullish outlook.

Key Facts

Q4 2025 revenue: $142.0 million (+41.6% YoY)
Full-year 2025 revenue: $502.7 million (+27.8% YoY)
Q4 2025 net loss: $7.5 million (vs. $13.2 million in Q4 2024)
Q4 2025 Adjusted EBITDA: $147K (vs. -$7.8M in Q4 2024)
Full-year 2025 Adjusted EBITDA: -$12.4M (improved from -$35.7M in 2024)
2026 guidance: Revenue $630M–$650M, Adjusted EBITDA $0–$9M
Cash flow from operations in Q4 2025: $3.2M
Cash and cash equivalents: $33.6M as of Dec 31, 2025

Financial Impact

Revenue growth accelerating (41.6% Q4 vs 27.8% full-year), with path to Adjusted EBITDA profitability in 2026. Gross profit grew 55.2% in Q4 and 41.6% for full-year 2025.

revenueepsadjusted_ebitdacash_flowgross_profit

Risk Factors

Guidance relies on non-GAAP metrics (Adjusted EBITDA, Free Cash Flow) without reconciliations, increasing uncertainty.
Seasonal headwinds in Q1 2026 expected to result in negative Adjusted EBITDA ($-1M to $-3M).
High reliance on capitated contracts and reimbursement timing lags could impact near-term cash flow.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3255105

4 reports for TOI

T+1T+5T+20T+60

Filters

Reports for TOI — sortable, filterable
	Type				Now
Jun 9, 2026 today	Insider Cluster NEUTRAL ★ 2/10	—	awaiting T+20	—	—
Apr 27, 2026 6w ago	Press Release NEUTRAL ★ 3/10	$3.33 $4.59	▲ +37.84%	▲ +32.88%	$4.96 (+48.95%)
Apr 9, 2026 8w ago	Insider Cluster MIXED ★ 5/10	$3.11 $3.80	▲ +22.19%	▲ +14.62%	$4.96 (+59.49%)
Mar 12, 2026 12w ago	Press Release BULLISH ★ 8/10	$2.84 $3.30	▲ +16.20%	▲ +12.61%	$4.96 (+74.65%)

US Market Status

Market Closed — Opens Thu (11h 16m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access